The UK and US have signed a important trade agreement that will preserve no import taxes on British drug shipments going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the NHS. This commitment ensures that duties on these vital goods will remain at nothing for a period of three years.
This deal is in response to earlier threats to hike tariffs on branded pharmaceutical products, with potential rates floated as high as double the cost.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and brings much-needed equity to American-British pharmaceutical trade," a statement said.
Economic Importance
Drugs represent one of the the United Kingdom's largest export categories to the United States, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to September, the UK exported medicines worth over eleven billion pounds to the US. This amount accounted for a significant portion of all goods exports in that span.
"This deal protects work, stimulates investment and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise total health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. Previously, refunds exceeded 20%.
Broader Context
The deal takes place against a ongoing tension between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by claims that US consumers were paying significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been announced toward US facilities.
One official publicly accepted that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the past decade.
